All In Biotech

Drug Trial Radar · NCT02694744

Patiromer With or Without Food for the Treatment of Hyperkalemia

The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Last checked: Nov 20, 2026Latest source record: May 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

114

Actual

Start

Feb 2016

Primary completion

Jul 2016

Study completion Aug 2016

Sponsor

Lead sponsor
Relypsa, Inc.Industry
Sponsor type
Industry
First posted
Feb 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).

Conditions

  • Hyperkalemia

Interventions

  • patiromerDrug

    8.4 g/day starting dose, administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Serum Potassium in the Target Range (3.8 - 5.0 mEq/L) at Either Week 3 or Week 4Time frame: 21 to 28 Days

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site 12

    Fountain Valley, California

  • Investigator Site 11

    Huntington Beach, California

  • Investigator Site 38

    Palm Springs, California

  • Investigator Site 20

    Riverside, California

  • Investigator Site 21

    San Dimas, California

  • Investigator Site 24

    Denver, Colorado

  • Investigator Site 30

    Edgewater, Florida

  • Investigator Site 10

    Hialeah, Florida

  • Investigator Site 13

    Hollywood, Florida

  • Investigator Site 17

    Lauderdale Lakes, Florida

  • Investigator Site 16

    Lauderdale Lakes, Florida

  • Investigator Site 15

    Miami, Florida

  • Investigator Site 43

    Miami, Florida

  • Investigator Site 18

    Pembroke Pines, Florida

  • Investigator Site 27

    Tampa, Florida

  • Investigator Site 44

    Meridian, Idaho

  • Investigator Site 39

    Aurora, Illinois

  • Investigator Site 23

    Flint, Michigan

  • Investigator Site 34

    Kansas City, Missouri

  • Investigator Site 41

    Las Vegas, Nevada

  • Investigator Site 37

    Flushing, New York

  • Investigator Site 36

    Norman, Oklahoma

  • Investigator Site 40

    Jackson, Tennessee

  • Investigator Site 33

    Dallas, Texas

  • Investigator Site 26

    San Antonio, Texas

  • Investigator Site 29

    San Antonio, Texas

  • Investigator Site 28

    San Antonio, Texas

  • Investigator Site 25

    San Antonio, Texas

  • Investigator Site 22

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.